Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arTreg-CSB (National Institute of Allergy and Infectious Diseases)
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
arTreg-CSB is an investigational adoptive cellular therapy consisting of donor alloantigen-specific CD4+ regulatory T cells (Tregs) expanded ex vivo using costimulatory blockade. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), it is designed to induce operational tolerance in liver transplant recipients, potentially allowing for the withdrawal of standard immunosuppressive medications. The therapy involves isolating Tregs from the recipient and expanding them in the presence of donor-derived cells and costimulatory blocking agents to create a population of cells specifically reactive to the donor's alloantigens. It is currently being evaluated in Phase I/II clinical trials.
- Other names
- alloantigen-reactive T regulatory cells with costimulatory blockadedonor alloantigen-specific CD4+ regulatory T cells
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)NECTIN1 (Poliovirus receptor-related 1)NeuraminidaseMHC II (Major histocompatibility complex class II receptor)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on arTreg-CSB (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arTreg-CSB (National Institute of Allergy and Infectious Diseases).